Survival in Thyroid Cancer in Sweden From 1999 To 2018

Frantisek Zitricky,1 Anni Koskinen,2,3 Kristina Sundquist,4– 6 Jan Sundquist,4– 6 Vaclav Liska,1,7 Asta Försti,8,9 Akseli Hemminki,10,11 Kari Hemminki1,4,12 1Biomedical Center, Faculty of Medicine, Charles University, Pilsen, Czech Republic; 2Department of Otorhinolaryngology- Head and Neck Surgery, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; 3Skin and Allergy Hospital, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; 4Center for Primary Health Care Research, Lund University, Malmö, Sweden; 5Department of Family Medicine and Community Health, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, USA; 6Center for Community-Based Healthcare Research and Education (Cohre), Department of Functional Pathology, School of Medicine, Shimane University, Shimane, Japan; 7Department of Surgery, Charles University Medical School, Pilsen, Czech Republic; 8Hopp Children’s Cancer Center (Kitz), Heidelberg, Germany; 9Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany; 10Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland; 11Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland; 12Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, GermanyCorrespondence: Kari Hemminki, Biomedical Center, Faculty of Medicine, Charles University Pilsen, Pilsen, 30605, Czech Republic, Email [email protected]: Thyroid cancer (TC) is diagnosed in several histological types which differ in their clinical characteristics and survival. We aim to describe how they influence TC survival in Sweden.Methods: Cancer data were obtained from the Swedish cancer registry between years 1999 and 2018, and these were used to analyze relative survival.Results: Relative survival for all TC improved when analyzed in 10-year periods, and female survival improved more than male survival. Female survival advantage appeared to be present also for specific histological types, although case numbers were low for rare types. Female 5-year relative survival for TC was 100% for follicular, 95.1% for oncocytic, 93.4% for papillary, 89.7% for medullary, and 6.1% for anaplastic cancer. Among the clinical TNM classes, only T4 and M1 stages were associated with decreased survival compared to T1-3 and M0. Anaplastic cancer presented most often at high T and M1 stages, in contrast to other TC. Curiously, the diagnostic age for anaplastic M1 patients was lower than that for M0 patients. Both anaplastic and medullary cancers did not show age-dependent increases in the probability of metastases, in contrast to the main histological types. This could indicate the presence of several types of anaplastic and medullary cancers.Conclusion: The poor survival for anaplastic TC is an extreme contrast to the excellent survival of differentiated TC. As less than 20% of anaplastic cancer patients survived one year, urgent diagnosis and initiation of treatment are important. Facilitated treatment pathways have been instituted in Denmark resulting in improved survival. Anaplastic cancer should be a target of a major research focus.Keywords: prognosis, relative survival, anaplastic cancer, metastasis, trends